Ardelyx (NASDAQ:ARDX – Get Free Report) and Relmada Therapeutics (NASDAQ:RLMD – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, earnings and valuation.
Valuation and Earnings
This table compares Ardelyx and Relmada Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ardelyx | $333.61 million | 5.72 | -$39.14 million | ($0.23) | -34.17 |
| Relmada Therapeutics | N/A | N/A | -$79.98 million | ($1.80) | -2.19 |
Volatility & Risk
Ardelyx has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, Relmada Therapeutics has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Ardelyx and Relmada Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ardelyx | 1 | 0 | 9 | 2 | 3.00 |
| Relmada Therapeutics | 1 | 0 | 3 | 0 | 2.50 |
Ardelyx presently has a consensus price target of $14.36, indicating a potential upside of 82.74%. Relmada Therapeutics has a consensus price target of $9.00, indicating a potential upside of 127.85%. Given Relmada Therapeutics’ higher possible upside, analysts clearly believe Relmada Therapeutics is more favorable than Ardelyx.
Insider & Institutional Ownership
58.9% of Ardelyx shares are held by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are held by institutional investors. 4.8% of Ardelyx shares are held by company insiders. Comparatively, 20.7% of Relmada Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Ardelyx and Relmada Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ardelyx | -14.20% | -36.91% | -12.57% |
| Relmada Therapeutics | N/A | -269.49% | -205.22% |
Summary
Ardelyx beats Relmada Therapeutics on 9 of the 14 factors compared between the two stocks.
About Ardelyx
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
About Relmada Therapeutics
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.
Receive News & Ratings for Ardelyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx and related companies with MarketBeat.com's FREE daily email newsletter.
